 |
|
|
Peramivir
|
|
| Systematic (IUPAC) name | |
| (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4- (diaminomethylideneamino)-2-hydroxy-cyclopentane- 1-carboxylic acid | |
| Identifiers | |
| CAS number | |
| ATC code | none |
| PubChem | |
| Chemical data | |
| Formula | C15H28N4O4 |
| Mol. mass | 328.407 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Peramivir is an experimental antiviral drug being developed by BioCryst Pharmaceuticals for the treatment of influenza .
Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells.
The development of peramivir is supported by the US Department of Health and Human Services as part of the US government's effort to prepare against the threat of an influenza pandemic.[1]
The drug has had a long history. An oral formulation was abandoned by Johnson and Johnson due to poor bioavailability.[2] BioCryst is now developing a injectable version, in partnership with Green Cross Pharmaceuticals in South Korea and with Shionogi Pharmaceuticals in Japan. The drug is in Phase II studies.[3][4]
References
- ^ US Department of Health and Human Services (2007-01-04). HHS Pursues Advance Development of New Influenza Antiviral Drug. Press release. http://www.hhs.gov/news/press/2007pres/20070104.html. Retrieved on 2007-05-25.
- ^ Pollack, Andrew (2005-10-07). "Talk of Bird Flu Pandemic Revives Interest in Passed-Over Drugs". New York Times. http://www.nytimes.com/2005/10/07/business/07drug.html?ex=1180411200&en=ccb286fb1a101436&ei=5070. Retrieved on 2007-05-25.
- ^ "Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza". National Institutes of Health. 2007-03-16. http://clinicaltrials.gov/show/NCT00419263. Retrieved on 2007-05-25.
- ^ "Evaluation of the Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-Threatening Influenza". National Institutes of Health. 2007-03-28. http://clinicaltrials.gov/show/NCT00453999. Retrieved on 2007-05-25.
|
||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
